New injection aims to control tough blood cancers in early trial
NCT ID NCT07493174
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called SYS6055 in 86 adults whose B-cell cancers (like certain leukemias or lymphomas) have come back or not responded to standard treatments. The main goals are to check safety, find the best dose, and see if it helps shrink tumors or control the disease. Participants must have CD19-positive cancer cells and be in fair health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time infusion of Dual-Target CAR-T cells outsmart resistant blood cancers?
- New cell therapy takes aim at Hard-to-Treat blood cancers
- Experimental Dual-Target CAR-T therapy enters human testing for tough blood cancers
- New CAR-T therapy targets tough blood cancers in early trial
- New shot takes on tough blood cancers in small safety trial
- New injection could train your body to fight cancer from within